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Background: Malaria remains the world’s most important devastating parasitic disease. Of the five species of
Plasmodium known to infect and cause human malaria, Plasmodium falciparum is the most virulent and responsible
for majority of the deaths caused by this disease. Mainstream drug therapy targets the asexual blood stage of the
malaria parasite, as the disease symptoms are mainly associated with this stage. The prevalence of malaria parasite
strains resistance to existing anti-malarial drugs has made the control of malaria even more challenging and hence
the development of a new class of drugs is inevitable.
Methods: Screening against different drug resistant and sensitive strains of P. falciparum was performed for few
bicyclic lactam-based motifs, exhibiting a broad spectrum of activity with low toxicity generated via a focussed
library obtained from diversity oriented synthesis (DOS). The synthesis and screening was followed by an in vitro
assessment of the possible cytotoxic effect of this class of compounds on malaria parasite.
Results: The central scaffold a chiral bicyclic lactam (A) and (A’) which were synthesized from (R)-phenylalaninol,
levulinic acid and 3-(2-nitrophenyl) levulinic acid respectively. The DOS library was generated from A and from A’ ,
by either direct substitution with o-nitrobenzylbromide at the carbon α- to the amide functionality or by conversion
to fused pyrroloquinolines. Upon screening this diverse library for their anti-malarial activity, a dinitro/diamine
substituted bicyclic lactam was found to demonstrate exceptional activity of >85% inhibition at 50 μM concentration
across different strains of P. falciparum with no toxicity against mammalian cells. Also, loss of mitochondrial membrane
potential, mitochondrial functionality and apoptosis was observed in parasite treated with diamine-substituted bicyclic
lactams.
Conclusions: This study unveils a DOS-mediated exploration of small molecules with novel structural motifs that
culminates in identifying a potential lead molecule against malaria. In vitro investigations further reveal their
cytocidal effect on malaria parasite growth. It is not the first time that DOS has been used as a strategy to
identify therapeutic leads against malaria, but this study establishes the direct implications of DOS in scouting
novel motifs with anti-malarial activity.
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Malaria, a leading cause of morbidity and mortality, is
still the world’s most important parasitic disease [1].
Globally, an estimated 3.4 billion people are at risk of
malaria. Out of all known species of malaria parasite,
Plasmodium falciparum causes the most virulent form
of malaria and is a leading infectious cause of morbidity
and mortality [2]. Of the nearly 1,400 drugs registered
worldwide in the last quarter of the 20th Century, only
four were anti-malarials [3]. No promising and efficient
anti-malarial vaccine is available despite various vaccines
being produced and tested [4,5]. Adding to the woes are
the prevalent P. falciparum strains resistant to the anti-
malarial drugs, such as chloroquine and artemisinin [6,7].
Despite this resistance, combination-based therapy can
continue to cure patients provided novel drugs are intro-
duced and included in the combination [8]. Therefore,
prompt endeavours are prerequisite to develop a new class
of drugs as chemotherapeutic anti-malarials.
Diversity oriented synthesis (DOS) is one of the lead-
ing approaches in present day drug discovery to identify
new class of compounds. It is considered one of the
most useful techniques, to provide distinct molecular
scaffolds that occupy different regions of chemical space
[9]. It utilizes a combination of building block-, appendage-,
stereochemical-, and skeletal-diversity to access structurally
disparate compounds [10]. Among these, skeletal diversity,
that deals with the scaffold architecture of the small mole-
cules, is the most important to attain.
Herein, chiral bicyclic lactams (A and A’) (the central
scaffolds of DOS-based strategy) were synthesized from
(R)-phenylalaninol/levulinic acid and 3-(2-nitro)levulinic
acid. The diversification strategies involved: (a) enolate-
mediated substitution with o-nitrobenzylbromide at the
carbon α –to the amide functionality (from A); and, (b)
lewis acid-based ring opening of the oxazoline ring of
the bicyclic lactams, followed by a 6-endo-trig ring clos-
ure to generate fused pyrroloquinolines (from A and A’).
The nitroaryl lactams were further reduced to generate
more lipophilic amines. Upon testing this focused library
for their anti-malarial activity, dinitro/diamine substituted
bicyclic lactams were found most effective growth inhibi-
tory compound against both drug-resistant clone Dd2 and
drug-sensitive clones HB3 and 3D7 of P. falciparum.
Methods
Chemical synthesis
Chiral bicyclic lactams A and A’ were synthesized from
(R)-phenylalaninol and levulinic acid and 3-(2-nitrophe-
nyl) levulinic acid. A was transformed to B1, B2, C and F
by substituting with various equivalents of o-nitrobenzyl-
bromide at the carbon α to the amide functionality or by
treating A with TiCl4 via a known procedure in the lit-
erature [11]. G was synthesized in a similar manner as F.The bicyclic lactam A was synthesized by condensa-
tion of R-phenylalaninol with levulinic acid in presence
of para-toluenesulfonic acid (PTSA) under toluene reflux
with excellent yield (84%) and high diastreoselectivity
(98%). Lactam A was alkylated with o-nitrobenzyl bromide
via enolate-mediated alkylation. A typical procedure in-
volved enolizing a tetrahydrofuran (THF) solution of A
at −78°C with lithium hexamethyl disilyl amide (LHMDS)
(2 eq.), followed by addition of o-nitrobenzylbromide
(1 eq.). The reaction was warmed to room temperature (RT)
and was monitored via liquid chromatography mass spec-
troscopy (LCMS). Once it indicated the completion of
mono-alkylation (which is after ~12 hour) half of the re-
action mixture was syringed to a different flask, then
quenched and purified to generate two monobenzylated di-
astereomers B1 and B2. The remaining reaction mixture
was further cooled to −78°C and then treated with LHMDS
(2 eq.), and stirred for about 30 minutes, followed by the
addition of an equivalent of o-nitrobenzylbromide. LCMS
monitoring indicated completion of the reaction by next
16 hours, after which it was quenched and purified to ob-
tain the dibenzylated bicyclic lactam C. Facile hydrogen-
ation with 10% w/w Pd-C and H2 (at atm pressure), of the
nitrobicyclic lactams B1/B2 and C generated the desired
amines E1/E2 and D.
In an effort to synthesize compound A’, 3-(2-nitrophenyl)
levulinic acid (12 g, 50.6 mmol), (R)-phenyl alaninol (7.3 g,
52 mmol) and PTSA (12 mg, cat) were dissolved in toluene
(120 mL and the flask (equipped with a Dean-Stark trap)
was heated to reflux. After 16 hours the solution was
cooled, washed with saturated aqueous NaHCO3, dried,
and concentrated. The final compound was purified by
flash column chromatography on silica gel as stationary
phase and Hexane/EtOAc, 1:1 as the eluent to afford the
desired compound, which was then triturated with diethyl
ether to afford the bicyclic lactam intermediate A’ (7.4 g,
41.5%) as white solid.
The intermediate A’ (500 mg, 1.42 mmol) was treated
with titanium chloride (TiCl4) (0.4 mL, 3.55 mmol) in
dichloromethane (DCM) (15 mL) and the resulting reac-
tion mixture was stirred at 20°C. Once thin layer chro-
matography (TLC) indicated complete consumption of
the starting material, the reaction was quenched with
saturated aqueous solution of NaHCO3 (20 mL) and was
filtered. The organic layer was separated and the aque-
ous layer was extracted further with dichloromethane
(DCM). The combined organic layers were dried over
sodium sulphate (Na2SO4) and evaporated to generate
compound G in 88:12 diastereomeric ratio. The major
product was purified by flash column chromatography.
Compounds B1, B2, C, D, E1, E2, F and G were dissolved
in dimethyl sulfoxide (DMSO; 10 mg/mL) (Sigma-Aldrich
Chemie GmbH, Buchs, Switzerland) and stored at 4°C for
use as anti-malarials.
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Plasmodium falciparum clones used in this study 3D7,
Dd2 and HB3 [12-14], were cultured in O+ human erythro-
cytes supplemented with RPMI 1640 (Invitrogen, USA) 24
mM sodium bicarbonate (Sigma, USA), 0.1 mM hypoxan-
thine (Invitrogen, USA), 25 mg/ml gentamicin (Invitrogen,
USA) and 0.5% AlbuMax I (Invitrogen, USA), according to
methods described earlier [15]. Parasite culture was main-
tained in mixed gas environment (5% O2, 5% CO2 and
90% N2). Parasites were synchronized by sorbitol treat-
ment at ring stage.
Kidney fibroblast-like cell lines (COS-7 cells) were cul-
tured in Dulbecco’s Modified Eagle’s Medium (Invitrogen,
USA) supplemented with 10% foetal bovine serum (Gibco,
USA) and penicillin (100 units/ml) and streptomycin (100
mg/ml). All cultures were incubated under standard cul-
ture conditions (37°C, 5% CO2).Growth inhibition assays
Compounds were tested at different concentrations for
inhibition of growth by P. falciparum strains 3D7, HB3
and Dd2. Briefly, the parasites were first synchronized by
the purification of schizont-stage parasites on a Percoll
gradient, followed by two rounds of treatment of the
ring-stage parasites with sorbitol. Schizont-stage para-
sites at an initial parasitaemia of 1% and at 2% haemato-
crit were incubated with compounds at concentrations
ranging from 0.5-50 μM, untreated as control, for one
cycle of parasite growth (40 hours post invasion). Follow-
ing a 40-hour incubation, the whole sample was collected
and washed twice with PBS and stained with ethidium
bromide (10 μM) for 15 minutes at room temperature in
dark. The cells were washed with PBS, and analysed
by flow cytometry on FACSCalibur (Becton Dickinson)
using CellQuest software [16]. Fluorescence signal (FL-2)
was detected with the 590 nm band pass filter using
an excitation laser of 488 nm collecting 100,000 cells
per sample. Following acquisition, parasitaemia was
estimated by detecting newly infected parasites, by deter-
mining the proportion of FL-2-positive cells using Cell
Quest.
Growth inhibition (% Inhibition) was calculated as follows:
% Inhibition ¼ 1− % Parasitaemia Treatmentð Þ =½
% Parasitaemia Controlð Þ  100:
Statistical analysis
The data for the IC50 values and % parasite growth are
expressed as the mean ± standard deviation (SD) of three
independent experiments done in duplicates. IC50 values
were calculated using Graph Pad Prism software.Progression assays
The effect of compounds showing most potent growth
inhibition (compounds C and D), was tested on progres-
sion of P. falciparum 3D7 strain at different stages (rings
(R), trophozoites (T), schizonts (S)) and release of mero-
zoites from schizonts. Ring-stage parasite culture was di-
luted to 2% parasitaemia and 2% haematocrit in a
complete RPMI medium and treated with compound
(50 μM) or solvent as control and incubated further for
12, 26, 48, and 54 hours blood-stage asexual cycle to
monitor progression at each stage. Morphological ana-
lysis and counting (~1,000 cells/Giemsa-stained slides in
duplicate) were done at each of these stages to monitor
progression. Giemsa-stained thin blood smears of P. fal-
ciparum were made at every 12, 26, 48, and 54 hours
post invasion and around 3,000 red blood cells (RBCs)
were counted by light microscopy. To determine the
relative per cent frequency of different stages of parasite
(R, T, S), a pie diagram was made using Graph Pad
Prism software.
Cytotoxicity assay with COS-7 cell line
COS-7 cells seeded in 96-well plates at a seeding density
of 30,000 cells per well were allowed to adhere overnight
at 37°C. Adhered cells were treated with compounds C and
D at 50 μM concentrations for 24 hours. Cytotoxic effect
was assessed using in vitro toxicology assay kit (Sigma-
Aldrich, St Louis, MO, USA), based on cleavage of MTT
((3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide)) by viable cells into formazan crystals.
Terminal deoxynucleotidyl transferase (TdT) mediated
dUTP nick end labelling (TUNEL) assay
Parasites at late ring/early trophozoite stages were treated
with either compound D or solvent alone and incubated
for 12 hours. The DNA fragmentation in treated and un-
treated samples was assessed by TUNEL using In Situ Cell
Death Detection Kit, TMR Red (Roche Applied Science),
as described previously [17]. Briefly, samples were fixed
with 4% paraformaldehyde (Sigma-Aldrich, Fluka Chemi-
cals) and 0.0075% glutaraldehyde in PBS for 30 minutes at
room temperature, washed with PBS and permeabilized
by 0.01% Triton-X 100. Following this, RBCs were incu-
bated with a mix of TdT enzyme and TMR Red labelled
dUTP for one hour at 37°C and washed thrice with 1X
PBS. The labelled parasites were then observed in Nikon
A1 confocal microscope and the percentage of TUNEL
positive cells were calculated.
JC-1 staining for estimation of mitochondrial membrane
potential
The cell permeable lipophilic cation probe JC-1 (Molecular
Probes, Eugene, OR, USA) exists as monomers in cyto-
plasm and emits green fluorescence (525 nm). Within the
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cence (590 nm) [18]. In healthy cells with high mitochon-
drial transmembrane potential the aggregates show an
intense red fluorescence. Cells in which the potential has
been lost show a weak red fluorescence and mostly green
fluorescence. A decrease in the red to green fluorescence
ratio therefore signifies a loss in the mitochondrial trans-
membrane potential. To estimate any changes in mito-
chondrial membrane potential, parasites treated with
compound D or solvent alone were incubated with 5 μM
JC-1 for 30 minutes at 37°C, washed twice with PBS and
imaged immediately using a Nikon A1 confocal micro-
scope. To avoid bias, images for both the sets were cap-
tured using the same laser intensity, voltage and offset
values in all the three channels. For each set, the ratio of
red to green fluorescence in 100 parasites from randomly
selected fields was estimated. For the estimation of fluores-
cence intensity in each channel, an infected and stained
RBC was selected using the Region of Interest (ROI) tool
provided in the Nikon NIS Elements AR Analysis V4.13.04
software. From this ROI area, the fluorescence intensity in
each channel was noted as given by the software in ROI
statistics. These values were used to calculate the ratio of
red to green fluorescence in 100 RBCs in those fields for
each set of parasite culture.
Results
Synthesis of substituted chiral bicyclic lactams and
pyrroloisoquinolines as potential anti-malarials
Substituted chiral bicyclic lactams B1 to E1 were synthe-
sized from A. A in turn was synthesized from (R)-phe-
nylalaninol and levulinic acid as depicted in the scheme
(Figure 1A). The final compounds were derived from A,
via enolization and alkylation with o-nitrobenzylbromide
and subsequent hydrogenation.
The diastereoselective alkylation of A afforded epimeric
o-nitrobenzylbicyclic lactams B1 and B2. Their subsequent
hydrogenation generated the corresponding amine E1 and
E2. In a different reaction, excess of base and prolonged re-
action time generated the dialkylated analog C that was also
hydrogenated to provide the amine D. In a separate effort
A was treated with TiCl4 in dichloromethane to undergo
the oxazoline ring opening, followed by a 6-endo-trig
cyclization to afford F. Finally, a novel bicyclic lactam A’
was synthesized by condensation of L-phenylalaninol with
2-(2-nitrophenyl)-levulinic acid. In a similar fashion as in
A’, it was converted to G.
In vitro growth inhibitory activity of substituted bicyclic
lactams against Plasmodium falciparum
Initially the screening of the biological activity of substituted
bicyclic lactams was done at different concentrations for
inhibition of intraerythrocytic growth by P. falciparum
strain 3D7. The compounds C, D, B1, B2, E1, F, and G(as mentioned in Methods) were tested at different con-
centrations over one cycle of parasite growth. The un-
treated parasites served as the control and percentage
growth inhibition was measured by flow cytometry. Com-
pound C exhibited 39.9 and 85.27% of growth inhibition
at 10 μM and 50 μM of concentration, respectively. Com-
pound D exhibited 25.24 and 77.84% of growth inhib-
ition at 10 μM and 50 μM of concentration, respectively
(Figure 1B, Additional file 1). Concurrently, other com-
pounds exhibited negligible effect (Figure 1B). This indi-
cated that the dinitro-substituted compound C and the
more lipophilic diamine-substituted compound D have
more significant effect on growth inhibition compared to
the other compounds in the same series (compound B1,
B2, E1, F, and G) and are thus the most potent of all the
substituted bicyclic lactams tested.
Half maximal inhibitory concentration (IC50) of compound
C and compound D
Compounds that demonstrated the most significant ef-
fect on parasite growth were further investigated for the
determination of the half maximal inhibitory concentra-
tion (IC50). Exploration of the half maximal inhibitory
concentrations (IC50) of compound C and D in dose-
dependent manner exhibited the IC50 value of 19.23 μM
and 23.03 μM, respectively (Figure 2A). The IC50 value
is based on the values after 40–44 hours of sorbitol syn-
chronized P. falciparum 3D7 clones at schizont-stage at
different concentrations of 0.5 μM, 1 μM, 5 μM, 10 μM,
20 μM, 25 μM, and 50 μM.
Stage-specific effect of compounds on Plasmodium
falciparum progression in vitro
Morphological analysis and counting (~3,000 cells/Giemsa-
stained slides in duplicate) over the 48-hour blood
stage cycle revealed healthy trophozoites 26 hours post-
invasion (hpi) either in presence or absence of compounds
(Figure 2B). At ~48 hpi healthy schizonts and new rings
were observed in solvent control but were >70% reduced
in the presence of either compound C or, compound D
(Figure 2B). Parasites remained stalled at early to late
trophozoites on treatment with compound C, D even
at ~54 hpi.
Growth inhibition activity of compounds across three
different strains of Plasmodium falciparum
Aforementioned results showed compounds C and D to be
the most effective for growth inhibition in P. falciparum
drug-sensitive strain 3D7. In order to further evaluate the
potential of compounds C and D, the growth inhibi-
tory activity of these compounds was assessed against
drug-resistant P. falciparum clone Dd2 and drug-sensitive
P. falciparum clone HB3 along with 3D7, over one cycle
at 10 μM and 50 μM of concentrations (Figure 3A,B).
Figure 1 (See legend on next page.)
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Figure 2 Effect of compounds C and D on parasite growth. (A) Percent parasite growth curve showing the effect of compounds C and D on
P. falciparum growth at different concentrations of 0.5 μM, 1 μM, 5 μM, 10 μM, 20 μM, 25 μM, and 50 μM. Three independent experiments were
performed in duplicates. (B) Comparison of parasite intra-erythrocytic maturation in presence and absence of compounds C and D. Light microscopy
Giemsa-stained images of P. falciparum-infected RBCs at 12, 26, 48, and 54 hpi incubated with and without compounds. Bars indicate relative percent
frequency of parasite ring, trophozoite and schizont stages in the 12, 26, 48, and 54 hpi. Healthy trophozoites are observed 26 hpi, either in presence or
absence of compounds. At 48 hpi, healthy new rings are observed in untreated control but, are >70% reduced in the presence of 50 μM of compound
C and compound D with parasite growth arrested as early and late trophozoites.
(See figure on previous page.)
Figure 1 Overview of the synthesis of substituted chiral bicyclic lactams as potential anti-malarials. (A) The scheme depicts the synthesis
of chiral bicyclic lactams from phenylalaninol/levulinic acid and 3-(2-nitrophenyl)levulinic acid. The final compounds were derived either via
enolization and alkylation with o-nitrobenzylbromide and subsequent hydrogenation or by lewis acid based ring opening and subsequent
cyclization. (B) Screening of synthesized compounds for P. falciparum growth-inhibitory activities at four different concentrations of 1 μM,
10 μM, 25 μM, and 50 μM. Bar graph indicates compounds C and D as the most potent inhibitor of P. falciparum growth. Three independent
assays were performed in duplicates. The error bars show the standard errors of the means.
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Figure 3 Growth-inhibitory activities of compounds across different Plasmodium falciparum strains and on viability of COS-7 cells.
(A) Bar graph showing the growth-inhibitory effect of dintro-substituted compound C at 50 μM concentration on sorbitol synchronized
P. falciparum drug-sensitive clones 3D7, HB3 and drug-resistant clones Dd2. (B) Bar graph showing the growth inhibitory effect of diamine-substituted
compound D at 50 μM concentration on sorbitol synchronized P. falciparum drug-sensitive clones 3D7, HB3 and drug-resistant clones Dd2.
Three independent assays were performed in duplicates. The error bars show the standard errors of the means. (C) Bar graph showing
percentage survival of COS-7 cells after 24 hours of treatment with compounds C and D. Three independent assays were performed in
duplicates. The error bars show the standard errors of the means.
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in drug-sensitive clones HB3 and 3D7, respectively,
whereas 34.24% in drug-resistant clone Dd2 at 10 μM of
concentration; also at 50 μM of concentration, it showed
85.27 and 88.35% of inhibition in drug-sensitive clones
3D7 and HB3, respectively, whereas 67.27% in drug-
resistant clone Dd2. Compound D exhibited the 77.84 and
79.34% of inhibition in drug-sensitive clones 3D7 and
HB3, respectively, whereas 59.3% in drug-resistant clone
Dd2 at 50 μM of concentration (Figure 3A,B). It is evident
from these data that the compounds show efficacy againstboth drug-sensitive as well as drug-resistant clones of
P. falciparum.
Effect of compounds on mammalian cell viability
Compounds C and D, having significant effect on growth of
malaria parasite, were further assessed for cytotoxic effects
on COS-7 mammalian cell line. The degree of cytotoxicity
caused was measured spectrophotometrically, based on the
protocol described previously by Mossmann [19]. No sig-
nificant cytotoxicity was observed at concentration as high
as 50 μM for both compounds C and D treated cells.
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parasite-mitochondrial membrane potential
The treated parasites were further examined for features
associated with cell death, alteration in mitochondrial
membrane potential and apoptosis. Ratio of JC-1 (red)/
JC-1 (green) was calculated to assess the loss of mitochon-
drial membrane potential. The JC-1 staining was observed
as strong red mitochondrial fluorescence and negligible
diffused green fluorescence (JC-1 monomer) across the
erythrocyte and parasite’s cytoplasm in solvent-treated
parasites, characteristic of a functional mitochondria as
(Figure 4A (i), (ii)). On the contrary, diffused green fluores-
cence (JC-1 monomer) was observed in ~60% of com-
pound D-treated parasites, suggesting loss of mitochondrial
membrane potential (Figure 4A (i), (ii)).
Compound D-induced apoptosis as detected via TUNEL
assay
Next, DNA fragmentation was assessed in treated and
untreated samples by TUNEL using In Situ Cell Death
Detection Kit, TMR Red (Roche Applied Science). The
labelled parasites were observed in Nikon A1 confocal
microscope and the percentage of TUNEL-positive cells
were calculated. The percentage of TUNEL-positive para-
sites after treatment with compound D increased by 60%
compared to solvent control (Figure 4B (i)). Also the fluor-
escent image of parasites treated with compound D,
stained with TMR Red (TUNEL staining) showed DNA
fragmentation (Figure 4B (ii)).
Discussion
Owning to immediate need of development of anti-
malarials, a new class of substituted bicyclic lactams was
developed and evaluated for their anti-malarial activity
against the asexual erythrocytic stage of P. falciparum.
Lactams are reported as a large class of antibiotics char-
acterized by the presence of the azetidin-2-one/oxazol-
2-one rings, which is the core of their biological activities.
They are further differentiated by side chains, unsatura-
tions, heteroatoms, and, in many cases, by the presence
of another five- or six-membered rings [20,21]. Biologic-
ally active lactams range from β-lactams, used in diverse
therapeutic areas viz serine-dependent enzyme inhibitors,
matrix-metalloprotease inhibitors, and even apoptosis in-
ductors [22,23], the inhibition of HIV-1 protease, antitumor
activity, anti-malarial activity, and cholesterol absorption
inhibition [24-30], peptides, bicyclic lactams (as potential
anticancer and anti-malarials) etc. This study, reports the
genesis (from DOS) of substituted bicyclic lactams and
their cyotoxic effect on malaria parasite growth, with the
objective to contribute new anti-malarial agents against
P. falciparum. It is not the first time DOS has been used
to generate efficacious small molecules against malaria.
Schreiber et al. has relentlessly researched on variouskinds of molecules ranging from small molecules to macro-
cycles evolved from DOS towards generating a therapeutic
compound against malaria. NITD-609, Novartis’ recent
molecule in phase 2 clinical trials for malaria is also the re-
sult of a DOS inspired effort. Additionally Brown et al.
also demonstrated the prowess of DOS in generating anti-
malarial compounds [31-35]. A DOS library was generated
from A and A’ by direct substitution with o-nitrobenzyl-
bromide at the carbon α to the amide functionality and
also converting A’ into fused pyrroloquinolines. A rational
chemistry-based approach is undertaken to design mole-
cules modifying the compounds for less toxicity, bioavail-
ability, more stability, solubility, and other attractive
features [36]. Based on preliminary screening results, the
dinitro-substituted bicyclic lactam has emerged as the
most active compound in the series. The nitro group in
compound C was consequently reduced to amine (com-
pound D) as amines are more soluble due to their hydro-
philic nature and hence are more bio-available compared
to their nitro counterpart. The nitroaryl lactams (com-
pound C) and the further reduced, more lipophilic amine
forms (compound D) demonstrated exceptional activity,
showing >85% inhibition at 50 μM concentration across
different drug-sensitive and drug-resistant strains of
P. falciparum (Figure 3A,B). It is noteworthy that the
introduction of modification attributed not much change
in antiparasitic activity as both compounds showed sig-
nificant effect on the parasite growth and exerted no
cytotoxic effect on mammalian cell line (Figure 3A,B,C).
Amines, being more soluble owing to their hydrophilic
nature, are more bio-available as compared to their nitro
counterpart, which will benefit further in vivo antiplasmo-
dial evaluation of the compound. Also the death of para-
site following in vitro exposure to compound D was
investigated using biochemical and morphological ap-
proaches. Diffused green fluorescence of JC-1 monomer
observed in compound D-treated parasites suggested a
loss of mitochondrial functionality and thus mitochondrial
membrane potential. TUNNEL assay further revealed the
presence of apoptotic cells in compound D-treated para-
sites. This study thus, establishes a strong demonstration
of the superior efficacy and cytotoxicity of substituted bi-
cyclic lactams against a broad range of P. falciparum
strains. These findings advocate a new class of compounds,
which could be considered as potential anti-malarials and
inclusion of these compounds in combination-based ther-
apy seems promising. The in vivo assessment of the anti-
parasitic potential of these bicyclic lactams could be
beneficial to achieve success in development of novel anti-
malarials and in eradication of this devastating disease.
Last but not the least the initial lead compound obtained
via our DOS strategy can be further elaborated and im-
proved into a better drug candidate in the future. There
are quite a few sites of diversity present in the molecules
Figure 4 Loss of mitochondrial membrane potential and apoptosis like cell-death in compound D-treated Plasmodium falciparum
parasites. (A) (i) Bar graph showing reduction in ratio of JC-1 (red)/JC-1 (green) in parasite population after treatment with compound
D. Two independent experiments were performed in duplicates. The error bars show the standard errors of the means. (ii) Fluorescent
images of JC-1-stained parasites showing aggregated JC-1 (red) in the mitochondria and monomeric JC-1 (green) in the cytoplasm after
treatment with solvent alone or compound D. Parasite nuclei were stained with DAPI (blue). (B) (i) Bar graph showing percentage of
TUNEL-positive parasites after treatment with compound D as compared to solvent alone (control). Two independent assays were performed in
duplicates. The error bars show the standard errors of the means. (ii) Fluorescent images of parasites stained with TMR Red (TUNEL staining) showing
DNA fragmentation after treatment with compound D.
Sharma et al. Malaria Journal 2014, 13:467 Page 9 of 11
http://www.malariajournal.com/content/13/1/467
Sharma et al. Malaria Journal 2014, 13:467 Page 10 of 11
http://www.malariajournal.com/content/13/1/467for example the aromatic ring of the benzylic moiety, the
oxazoline side ring which can be changed to thiazoline
side chain, the subsequent reduction of the nitro group
followed by diverse array of acid-amine coupling or C-N
bond formation reactions with aliphatic, aromatic and het-
eroaromatic halides and finally, further substituting the
position α- to the amide carbonyl either by alkylation or
by acylation will provide opportunities to improve the effi-
cacy of this initial lead compound.
Additional file
Additional file 1: Growth inhibition activity of substituted bicyclic
lactams. Growth-inhibitory activities of compounds C, D, B1, B2, E1,
F, and G. Compounds were assayed at two different concentrations
of 10 μM and 50 μM in sorbitol synchronized P. falciparum 3D7 clones.
Three independent assays were performed in duplicate. §SEM is standard
error of means.
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